Transparent citation kiting in the 2013 EAS “consensus statement”

The 2013 “consensus statement of the European Atherosclerosis Society” was published in the European Heart Journal. It can be seen below, on the right. It is the most influential statement of FH prevalence in the industry, found in FDA documents, investor presentations, patient brochures, and even in SEC 10-K filings. It puts FH prevalence at 1/200. This number is converted in the 2014 EAS statement through the “Hardy-Weinberg” equation to the HoFH population of 1/160,000. (See for more detail.) I found many shenanigans in these reports, and I hope to go public with those in separate presentations. For the present purposes, we’ll focus on the linguistic manipulation executed by way of citation kiting. On the left is Dr. Rader’s 2003 report, with the established definition of FH: it is distinct from the APOB and PCSK9 carriers. On the right is the 2013 EAS report which cites Dr. Rader’s paper, but it conflates the diseases together.  Combining FH, FDB, and FH3 in the 2003 report on the left leaves us with 1 in 300.  Most of the 1 in 200 in the 2013 report on the right is due to this linguistic maneuver.  (As for getting from 1 in 300 to 1 in 200, I will cover that in a separate presentation.)

Familial hypercholesterolemia, LDLR, APOB and PCSK9, FH patients